Moreover, aberrant VDAC2 expression or functioning has been reported in multiple tumors, including melanoma, epithelial thyroid tumors, and breast cancer, indicating that targeting VDAC2 is of therapeutic significance for cancer treatment37–39. The gene discussed is VDAC2; the disease is breast carcinoma.